Project Grant R01AI183381
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $489,500.00 to The Children's Hospital of Philadelphia to investigate the cellular identity of the intact HIV reservoir. The key objectives are to: Test the hypothesis that CD4+ T cells with provirus in closed chromatin are transcriptionally distinct from cells with provirus in open chromatin (Aim 1). Test the hypothesis that cells with...
- This $251,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support a clinical trial planning project focused on evaluating the use of adeno-associated virus (AAV)-delivered broadly neutralizing antibodies (bnAbs) to achieve durable control of HIV-1 in children after discontinuation of antiretroviral therapy (ART). The award to the University of Massachusetts Medical School will help develop a full...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $240,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Northwestern University to conduct research on characterizing the HIV-1 viral reservoirs that persist even under antiretroviral therapy (ART). The 2-year project aims to identify the cellular sources and genetic diversity of the HIV-1 reservoirs, as well as study the sources and characteristics of the residual viremia...
- This $1,332,155 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to Emory University aims to conduct a systematic analysis of optimization strategies for broadly neutralizing antibody (BnAb) immunotherapy in the unique setting of postnatal HIV infection in infants. The key objectives are to: 1) Define how NF-kB pathway activation with BnAb administration during early ART impacts viral reservoir...
- This Project Grant award of $800,389.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The proposed treatment combines soluble IL-15/IL-15RA-FC with a TGF-β pathway blockade and therapeutic vaccination to enhance and restore anti-viral immunity, leading to sustained viral remission...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $698,390 to the Regents of the University of California at Riverside to conduct research aimed at harnessing innate immunity to control the neuroinflammatory HIV reservoir. The key objectives are to investigate how HIV infection triggers an interferon (IFN) response, how HIV...
- The federal Project Grant awarded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will fund research to obtain new insights into gut dysbiosis and inflammatory signaling cascades related to metabolic disturbances in youth with perinatally acquired HIV (YPHIV) in sub-Saharan Africa. The $265,369 award to the Ann & Robert H Lurie Children's Hospital of Chicago...
- The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) awarded a $232,500 Project Grant under the Child Health and Human Development Extramural Research program (CFDA 93.865) to The Johns Hopkins University. The grant supports research to investigate the virologic determinants that lead to long-term antiretroviral therapy-free control in a subset of infants infected with HIV-1 in utero. Key research activities include: Creating infectious molecular clones...
- This $812,810 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Emory University to generate highly differentiated natural killer (NK) cells and evaluate their synergistic effects with broadly neutralizing antibodies in reducing the SIV reservoir and establishing viral control in the absence of antiretroviral therapy (ART). The key objectives are to: 1) define...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,414,502 to the University of North Carolina at Chapel Hill (UNC-CH) to conduct research on assessing the variability in antiretroviral (ARV) drug penetration within tissues as a potential factor contributing to the persistence of HIV during treatment. The research aims to leverage advanced imaging techniques,...
HIGH RESOLUTION INFLAMMATORY NETWORKS INDUCED BY HIV RESERVOIRS IN ADOLESCENTS - ABSTRACT ANTIRETROVIRAL TREATMENT (ART) FOR HIV INFECTION EFFECTIVELY BLOCKS VIRAL REPLICATION, BUT FAILS TO ERADICATE THE VIRUS, WHICH CAN BE A SOURCE OF PERSISTENT INFLAMMATION. THE PATHWAYS BY WHICH CHRONIC, TREATED HIV INFECTION DRIVES INFLAMMATION ARE POORLY DEFINED, PARTICULARLY IN CHILDREN AND ADOLESCENTS WHO ACQUIRE HIV PERINATALLY. PERINATAL HIV INFECTION OCCURS IN THE CONTEXT OF A DEVELOPING IMMUNE SYSTEM, REQUIRES LIFE-LONG TREATMENT, AND EVEN WITH EFFECTIVE ART, TREATMENT IS ASSOCIATED WITH INCREASED RISKS OF METABOLIC, NEUROCOGNITIVE AND CARDIOVASCULAR COMPLICATIONS THAT RESULT FROM THIS HIV-INDUCED INFLAMMATION. THUS, TO UNDERSTAND THE MECHANISMS DRIVING INFLAMMATION IN THIS VULNERABLE POPULATION THAT FACES DECADES-LONG INFECTION AND TREATMENT, WE WILL STUDY HIV-INDUCED INFLAMMATION IN A UNIQUE COHORT OF PERINATALLY INFECTED ADOLESCENTS IN KENYA WHO HAVE BEEN MAINTAINED ON ART AND FOLLOWED CLINICALLY SINCE THEIR FIRST YEAR OF LIFE. TO COMPLEMENT THESE VALUABLE LONGITUDINAL CLINICAL SAMPLES, WE HAVE DEVELOPED ORGANOIDS OF HUMAN SECONDARY LYMPHOID TISSUES, A MAJOR HIV RESERVOIR SITE. THE LYMPHOID ORGANOIDS WE ARE USING ARE HIGHLY RELEVANT TO PEDIATRIC AND ADOLESCENT INFECTIONS AS THEY ARE DERIVED FROM PEDIATRIC/ADOLESCENT TISSUE, CONTAIN ALL MAJOR IMMUNE CELL TYPES, INFECTABLE WITH HIV, AND ARE MANIPULABLE VIA GENE EDITING, SIRNA TRANSFECTION, AND ANTIBODY/SMALL MOLECULE INHIBITORS TO PROBE MECHANISMS DRIVING HIV-INDUCED INFLAMMATION. OUR GOAL IS TO USE THESE UNIQUE RESOURCES TO IDENTIFY HIV-INDUCED INFLAMMATORY NETWORKS IN PERINATALLY-INFECTED ADOLESCENTS ON LONG-TERM ART AND TO DEFINE THE VIRAL FACTORS THAT DRIVE HIV-INDUCED INFLAMMATION. WE WILL MAKE USE OF SINGLE CELL TECHNIQUES, WHICH TO DATE HAVE ONLY BEEN APPLIED TO ADULT COHORTS, TO MAP THE CELL-INTRINSIC INFLAMMATORY NETWORKS INDUCED DURING CHRONIC TREATED HIV INFECTION AND DEFINE THE VIRAL GENES THAT INITIATE THESE CASCADES. IN ADDITION, TO FILL A GAP THAT HAS BEEN MISSING IN PRIOR STUDIES, WE SEEK TO UNDERSTAND HOW THESE RARE INFECTED CELLS INITIATE DOWNSTREAM CASCADES OF INFLAMMATION THAT DRIVE PATHOLOGY BY STUDYING COMMUNICATION NETWORKS USING METHODS WE RECENTLY DEVELOPED TO INFER CELL-CELL COMMUNICATION AT THE SINGLE CELL LEVEL. THIS POWERFUL COMBINATION OF A LONG-TERM PEDIATRIC TREATMENT COHORT COUPLED WITH MECHANISTIC STUDIES IN A ROBUST EX VIVO LYMPHOID CULTURE SYSTEM WILL PROVIDE A UNIQUE WINDOW INTO HIV-INDUCED INFLAMMATION. SUCCESSFUL COMPLETION OF THIS PROJECT WILL DEFINE MECHANISMS BY WHICH RESIDUAL HIV RNA EXPRESSION DURING TREATED INFECTION DRIVES INFLAMMATION IN PERINATALLY INFECTED ADOLESCENTS AND ESTABLISH MODELS TO TEST THERAPEUTICS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $775.5k | 8/5/25 | ||
| Not listed | $815.6k | 7/29/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
63588333311073S | Fred Hutchinson Cancer Center | Project Grant R01AI183381 | $140.8k | 1/13/25 | |
63560820311073S | University Of Washington | Project Grant R01AI183381 | $85.5k | 10/11/24 |